Recent research identifies a specific fatty acid metabolite in neonatal blood that influences the severity of autism spectrum disorder (ASD) symptoms. This discovery could enable early diagnosis and intervention, potentially improving outcomes for those affected by ASD. Autism spectrum disorder (ASD) is a neurodevelopmental condition that influences the learning abilities and social interactions of individuals.
In recent decades, there has been a significant increase in awareness about ASD, including its occurrence and impact on those who are diagnosed. Nevertheless, many facets of ASD remain poorly understood, indicating that there is still much to learn. Although the exact causes of ASD are unclear, currently available evidence points to neuroinflammation as a major factor.
Several studies in mouse models of ASD have hinted at the importance of polyunsaturated fatty acids (PUFA) and their metabolites during pregnancy in playing a key role in ASD development. PUFA metabolites regulated by the cytochrome P450 (CYP) affect fetal development in mice causing impairments closely linked to ASD symptoms. However, it is still unclear if the same is true for humans and needs further investigation.
Study on CYP-PUFA Levels and ASD To address this knowledge gap, a research team from Japan consisting of Professor Hideo Matsuzaki from the Research Center for Child Mental Development, University of Fukui, Dr. Takaharu Hirai at the Department of Psychiatric and Mental Health Nursing, Schoo.